Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.

Abstract: The present invention relates to a process for the preparation of a polyarylene ether sulfone polymer (P) by converting a reaction mixture (RG) which comprises, among others, at least one aromatic dihalogen sulfone and at least one dihydroxy component comprising at least 20 mol-% of trimethylhydroquinone based on the total amount of the at least one dihydroxy component. The present invention furthermore relates to the Ouse of a polyarylene ether sulfone polymer (P) obtainable by the inventive process in a membrane (M) and to a membrane (M) comprising the polyarylene ether sulfone polymer (P) obtainable by the inventive process, as well as to a method for the preparation of a membrane (M).

Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.

Abstract: An intermediate of the formula (I) wherein the radicals R1 are independently of one another methyl, ethyl or n-propyl, is suitable for preparing a compound of the formula (A) wherein X is a group of the formula (A-I) or (A-II), Y is C11-C17alkyl, and Z is a direct bond, —(CH2)8— or —CH2—S—CH2—. The compounds of the formula (A) are useful for stabilizing an organic material against thermal, oxidative or light induced degradation.

Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.

Abstract: The present invention relates to a process for the preparation of a polyarylethersulfone-polyalkylene oxide block copolymer (PPC) by converting a reaction mixture (RG) which comprises, among others, at least one aromatic dihalogen sulfone, at least one dihydroxy component comprising trimethylhydroquinone and at least one polyalkylene oxide. The present invention furthermore relates to a polyarylethersulfone-polyalkylene oxide block copolymer (PPC) obtainable by the inventive process and to its use in a membrane (M) and to a membrane (M) comprising the polyarylethersulfone-polyalkylene oxide block copolymer (PPC). Furthermore, the present invention relates to a method for the preparation of a membrane (M).

Abstract: The present invention relates to a process for the preparation of a sulfonated polyarylene ether sulfone polymer (sP) by converting a reaction mixture (RG) which comprises, among others, at least one non-sulfonated aromatic dihalogen sulfone, at least one sulfonated aromatic dihalogen sulfone and at least one aromatic dihydroxy component comprising trimethylhydroquinone. The present invention furthermore relates to a sulfonated polyarylene ether sulfone polymer (sP) obtainable by the inventive process and to its use in a membrane (M). Furthermore, the present invention relates to a membrane (M) comprising this sulfonated polyarylene ether sulfone polymer (sP) and to a method for the preparation of the membrane (M).

Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.

Abstract: An intermediate of the formula (I) wherein the radicals R1 are independently of one another methyl, ethyl or n-propyl, is suitable for preparing a compound of the formula (A) wherein X is a group of the formula (A-I) or (A-II), Y is C11-C17alkyl, and Z is a direct bond, —(CH2)8— or —CH2—S—CH2—. The compounds of the formula (A) are useful for stabilizing an organic material against thermal, oxidative or light induced degradation.

Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.

Abstract: The invention relates to a composition comprising an organic material susceptible to oxidative, thermal or light-induced degradation and a compound of formula I-P, I-O or I-M Further embodiments are a compound of formula I-P, I-O or I-M, a process for protection of the organic material by the compound, the use of the compound for stabilizing the organic material, an additive composition comprising the compound, a process for manufacturing the compound and intermediates involved therein.

Abstract: The present invention relates to a process for the preparation of 2,6-di-tert-butyl phenol by reacting phenol with isobutylene in presence of an aluminum phenoxide catalyst, comprising i) preparing an aluminum phenoxide catalyst and phenol comprising mixture a) by mix-ing aluminum metal with phenol, and activating the catalyst by heating the mixture to a temperature of 100 to 180° C., and ii) carrying out a reaction b) by reacting mixture a) with an isobutylene comprising stream comprising 20 to 90% by weight of isobutylene and 10 to 80% by weight of 1-butene and/or 2-butene, which reaction is carried out under pressure and the maximum pressure is 5 to 20 bar.

Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.

Abstract: A composition, which comprises a) an organic material susceptible to oxidative, thermal or light-induced degradation; and b) a compound of formula I (Formula I) (I) where R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are independently from each other H, C1-C8-alkyl, C4-C8-cycloalkyl, phenyl, C1-C4-alkoxy or halogen; n is 1, 2, 3, or 4; and when n is 1 A is —C(=0)-OR?1, —C(=0)-N(R?2)(R?3), —CN, phenyl, which is unsubstituted or substituted by one or more C1-C8-alkyl, C4-C8-alkoxy, C5-C7-cycloalkyl or halogen, —H or —S02-phenyl; when n is 2 A is —C(=0)-0-Z1—O—C(=0)-, —C(=0)-N(R?1)—Z2—N(R?2)—C(=0)- or piperazine-N,N?-biscarbonyl.

Abstract: The invention relates to a composition comprising an organic material susceptible to oxidative, thermal or light-induced degradation and a compound of formula I-P, I-O or I-M. Further embodiments are a compound of formula I-P, I-O or I-M, a process for protection of the organic material by the compound, the use of the compound against degradation of the organic material, an additive composition comprising the compound, a process for manufacturing the compound and an intermediate involved therein.

Abstract: The present invention relates to a process for the preparation of 2,6-di-tert-butyl phenol by reacting phenol with isobutylene in presence of an aluminum phenoxide catalyst, comprising i) preparing an aluminum phenoxide catalyst and phenol comprising mixture a) by mix-ing aluminum metal with phenol, and activating the catalyst by heating the mixture to a temperature of 100 to 180° C., and ii) carrying out a reaction b) by reacting mixture a) with an isobutylene comprising stream comprising 20 to 90% by weight of isobutylene and 10 to 80% by weight of 1-butene and/or 2-butene, which reaction is carried out under pressure and the maximum pressure is 5 to 20 bar.

Abstract: The invention relates to a composition comprising an organic material susceptible to oxidative, thermal or light-induced degradation and a compound of formula I-P, I-O or I-M Further embodiments are a compound of formula I-P, I-O or I-M, a process for protection of the organic material by the compound, the use of the compound for stabilizing the organic material, an additive composition comprising the compound, a process for manufacturing the compound and intermediates involved therein.

Abstract: The present invention relates to symmetric diesters of hydroxyalkyl-4-hydroxy-tetraalkylpiperidine compounds and their use as light stabilizers. They are compatible with and soluble in coating formulations of different polarity.

Abstract: The invention relates to a composition comprising an organic material susceptible to oxidative, thermal or light-induced degradation and a compound of formula 1-P, 1-O or I-M. Further embodiments are a compound of formula 1-P, 1-O or 1-M, a process for protection of the organic material by the compound, the use of the compound for stabilizing the organic material, an additive composition comprising the compound, a process for manufacturing the compound and intermediates involved therein.

Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.